Market Cap 304.65M
Revenue (ttm) 30.91M
Net Income (ttm) -74.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -240.31%
Debt to Equity Ratio 0.00
Volume 81,000
Avg Vol 151,410
Day's Range N/A - N/A
Shares Out 58.70M
Stochastic %K 68%
Beta 3.11
Analysts Strong Sell
Price Target $11.44

Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-ce...

Industry: Biotechnology
Sector: Healthcare
Phone: 617-586-3100
Address:
99 Coolidge Avenue, Suite 500, Watertown, United States
TimmyGainZ
TimmyGainZ Apr. 23 at 4:11 PM
0 · Reply
focafoca99
focafoca99 Apr. 21 at 8:47 PM
$FHTX showed new preclinical data across several programs, including complete and durable tumor regression for FHD-909 in combination with anti-PD-1 in mouse models.
0 · Reply
focafoca99
focafoca99 Apr. 9 at 7:53 PM
$FHTX will present new preclinical AACR data on FHD-909 and several degrader programs.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 1:00 AM
$FHTX Q4 '25 Earnings Results & Recap Foghorn Therapeutics Inc. expects its cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures for at least twelve months, with $249.2M in deferred revenue expected through 2029 or beyond.
0 · Reply
d_risk
d_risk Mar. 12 at 12:32 AM
$FHTX - Foghorn Therapeutics Inc - 10K - Updated Risk Factors FHTX flags new risks from AI/ML use, shifting federal healthcare and FDA policies (including post-Loper regulatory uncertainty and IRA implementation), and political/administrative changes that could slow approvals, raise compliance costs, and pressure pricing, while dropping emerging-growth-company status as a distinct risk. #Biotechnology #AIMLIntegration #HealthcareRegulation #FDAApproval #PricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/FHTX/10-K/2026-03-11
0 · Reply
Abron
Abron Mar. 9 at 3:51 PM
$FHTX Every day the same tning
0 · Reply
NorthStarStats
NorthStarStats Mar. 8 at 4:39 PM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $KR Score:90.00 (BREAKOUT WATCH), $SLDB Score: 95.00; MDA Conf.,Earnings,Phase 3 Trial, $GHRS Score: 95.00; Phase 3 Start Announcement, $FHTX Score: 85.00;Cash Runaway, $SBUX Score 70.00; Revenue +6% 600-650 new stores
0 · Reply
Abron
Abron Feb. 26 at 3:33 PM
$FHTX every day same thing
0 · Reply
BioTuesdays
BioTuesdays Feb. 23 at 2:51 PM
$FHTX has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. https://biotuesdays.com/2026/02/23/foghorn-appoints-ryan-maynard-as-cfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 11:51 PM
$FHTX RSI: 50.43, MACD: 0.0250 Vol: 0.20, MA20: 5.65, MA50: 5.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on FHTX
Foghorn Therapeutics Transcript: AACR Annual Meeting 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Transcript: AACR Annual Meeting 2025


Foghorn Therapeutics Transcript: Status Update

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Transcript: Status Update


TimmyGainZ
TimmyGainZ Apr. 23 at 4:11 PM
0 · Reply
focafoca99
focafoca99 Apr. 21 at 8:47 PM
$FHTX showed new preclinical data across several programs, including complete and durable tumor regression for FHD-909 in combination with anti-PD-1 in mouse models.
0 · Reply
focafoca99
focafoca99 Apr. 9 at 7:53 PM
$FHTX will present new preclinical AACR data on FHD-909 and several degrader programs.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 1:00 AM
$FHTX Q4 '25 Earnings Results & Recap Foghorn Therapeutics Inc. expects its cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures for at least twelve months, with $249.2M in deferred revenue expected through 2029 or beyond.
0 · Reply
d_risk
d_risk Mar. 12 at 12:32 AM
$FHTX - Foghorn Therapeutics Inc - 10K - Updated Risk Factors FHTX flags new risks from AI/ML use, shifting federal healthcare and FDA policies (including post-Loper regulatory uncertainty and IRA implementation), and political/administrative changes that could slow approvals, raise compliance costs, and pressure pricing, while dropping emerging-growth-company status as a distinct risk. #Biotechnology #AIMLIntegration #HealthcareRegulation #FDAApproval #PricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/FHTX/10-K/2026-03-11
0 · Reply
Abron
Abron Mar. 9 at 3:51 PM
$FHTX Every day the same tning
0 · Reply
NorthStarStats
NorthStarStats Mar. 8 at 4:39 PM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $KR Score:90.00 (BREAKOUT WATCH), $SLDB Score: 95.00; MDA Conf.,Earnings,Phase 3 Trial, $GHRS Score: 95.00; Phase 3 Start Announcement, $FHTX Score: 85.00;Cash Runaway, $SBUX Score 70.00; Revenue +6% 600-650 new stores
0 · Reply
Abron
Abron Feb. 26 at 3:33 PM
$FHTX every day same thing
0 · Reply
BioTuesdays
BioTuesdays Feb. 23 at 2:51 PM
$FHTX has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. https://biotuesdays.com/2026/02/23/foghorn-appoints-ryan-maynard-as-cfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 11:51 PM
$FHTX RSI: 50.43, MACD: 0.0250 Vol: 0.20, MA20: 5.65, MA50: 5.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 11:36 PM
$FHTX Current Stock Price: $5.45 Contracts to trade: $5.0 FHTX Feb 20 2026 Call Entry: $2.21 Exit: $4.27 ROI: 93% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
wyoming2020
wyoming2020 Feb. 7 at 12:27 PM
$FHTX CEO big buy at Foghorn $ACIU $PDSB fam check it out
0 · Reply
kimmynjgrl
kimmynjgrl Feb. 3 at 11:19 PM
$FHTX One min video... https://youtube.com/shorts/tLWJo9AlexE?feature=share
0 · Reply
vu_jade
vu_jade Feb. 2 at 4:21 PM
$FHTX get your Foghorn LEG”horn” up
0 · Reply
vu_jade
vu_jade Jan. 28 at 8:31 PM
$FHTX ADDED
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 2:08 PM
$FHTX Share Price: $5.87 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.23 – $1.52 Target Zone: $2.14 – $2.61 Potential Upside: 64% ROI Time to Expiration: 144 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
vu_jade
vu_jade Jan. 21 at 8:43 PM
$FHTX great set up
0 · Reply
oneyedjacks
oneyedjacks Jan. 12 at 8:29 PM
$FHTX I Say I say Bullish
1 · Reply
vu_jade
vu_jade Jan. 12 at 7:46 PM
$FHTX howdy
0 · Reply
LabPsycho
LabPsycho Jan. 12 at 6:50 PM
$FHTX $PRLD @Stmkr mysteriously prld pause smarca2 = 100% price increase. Something else seems to be going on? I've posted my conspiracy theories for rebuking. Worst part is all the time I wasted creating a simulation with their molecule. Maybe I should work on a molecular model for FHTX...however such a huge time and effort drain in the research and set up required to get one to work and hardly anyone seems to care about these molecular dynamic simulations I post. Hmm...what to do?
1 · Reply
OpenOutcrier
OpenOutcrier Jan. 12 at 1:54 PM
$FHTX (+6.4% pre) Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 https://ooc.bz/l/89377
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 11 at 11:40 PM
$FHTX Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 "Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026"
0 · Reply